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SUMMARY 25 
The Melanocortin 4 Receptor (MC4R) is a G-protein coupled receptor whose disruption 26 
causes obesity. We functionally characterized 61 MC4R variants identified in 0.5 million 27 
people from UK Biobank and examined their associations with Body Mass Index (BMI) and 28 
obesity-related cardiometabolic diseases. We found that the maximal efficacy of β-arrestin 29 
recruitment to MC4R, rather than canonical Gαs-mediated cyclic adenosine-monophosphate 30 
production, explained 88% of the variance in the association of MC4R variants with BMI. 31 
Whilst most MC4R variants caused loss-of-function, a subset caused gain-of-function; these 32 
variants were associated with significantly lower BMI, and lower odds of obesity, type 2 33 
diabetes and coronary artery disease. Protective associations were driven by MC4R variants 34 
exhibiting signaling bias towards β-arrestin recruitment and increased Mitogen-Activated 35 
Protein Kinase pathway activation. Harnessing β-arrestin-biased MC4R signaling may 36 
represent an effective strategy for weight loss and the treatment of obesity-related 37 
cardiometabolic diseases.  38 
 39 
 40 
  41 




Obesity is associated with type 2 diabetes and coronary artery disease, which together 44 
account for significant morbidity, mortality and substantial health care costs globally 45 
(Heymsfield and Wadden, 2017). Whilst advances in our understanding of the molecular 46 
mechanisms involved in weight regulation have informed the development of new weight 47 
loss therapies, some drugs lack target specificity whilst others affect multiple signaling 48 
pathways downstream of their intended target leading to adverse effects which limit their 49 
long-term use (Bray et al., 2016). Therefore, there is a substantial unmet need for safe and 50 
effective weight loss therapies.  51 
 52 
G protein-coupled receptors (GPCRs) are targeted by approximately 30% of US Food and Drug 53 
Administration (FDA)-approved medicines highlighting their tractability for drug discovery 54 
(Hauser et al., 2017; Santos et al., 2017). Classically, upon ligand binding GPCRs interact with 55 
heterotrimeric Guanine nucleotide-binding (G) proteins to direct signaling and gene 56 
transcription, a response which is attenuated within minutes when phosphorylated GPCRs 57 
bind β-arrestins which sterically prevent their coupling to G proteins (Rajagopal and Shenoy, 58 
2018). This molecular interaction also promotes the internalization of ligand-bound receptors  59 
to early endosomes, from where GPCRs either recycle rapidly to the cell membrane or 60 
translocate to lysosomes for degradation (Shenoy and Lefkowitz, 2011; Shinyama et al., 61 
2003). β-arrestins may also directly/indirectly mediate signaling via Mitogen-Activated 62 
Protein Kinase (MAPK)-mediated phosphorylation of extracellular signal-regulated kinase 1/2 63 
(ERK1/2).  64 
 65 
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Whilst balanced GPCR agonists signal with comparable efficacy through multiple pathways, 66 
the development of biased agonists which preferentially activate signaling through either G 67 
protein-dependent or G protein-independent β-arrestin-mediated pathways, is emerging as 68 
a powerful way of emphasizing favorable signals whilst de-emphasizing signals that may lead 69 
to adverse effects (Povsic et al., 2017; Rajagopal et al., 2011; Smith et al., 2018). Such targeted 70 
drug discovery relies on the precise delineation of the relative contributions of G proteins 71 
versus β-arrestins to the physiological consequences of GPCR activation.  72 
 73 
Here we focused on the Melanocortin 4 Receptor (MC4R), a brain-expressed Gαs-coupled 74 
GPCR involved in weight regulation (Fan et al., 1997; Kishi et al., 2003; Mountjoy et al., 1994; 75 
Ollmann et al., 1997). Feeding-induced release of the melanocortin peptides, - and β-76 
melanocyte-stimulating hormone (MSH), leads to activation of MC4R-expressing neurons  77 
resulting in reduced food intake (Cowley et al., 2001; Fan et al., 1997). Targeted deletion of 78 
Mc4r in rodents causes weight gain in a gene dosage-dependent manner (Huszar et al., 1997). 79 
In humans, rare heterozygous MC4R variants that reduce Gαs-mediated cyclic adenosine-80 
monophosphate (cAMP) accumulation in cells have been identified in obese children and 81 
adults in many populations (Vaisse et al., 1998)(Yeo et al., 1998) (www.mc4r.org.uk). MC4R 82 
deficiency in rodents and humans (Fan et al., 2000; Farooqi et al., 2003) is characterized by 83 
low blood pressure (for the degree of obesity) due to impaired sympathetic nervous system 84 
activation (Greenfield et al., 2009) (Sayk et al., 2010; Simonds et al., 2014; Tallam et al., 2005). 85 
As predicted by these genetic findings, first generation MC4R agonists caused weight loss but 86 
increased blood pressure (BP) (Greenfield et al., 2009), which halted their development. A 87 
second generation MC4R agonist reduced weight in rare patients with obesity due to genetic 88 
disruption of the melanocortin pathway (Clement et al., 2018; Collet et al., 2017; Kuhnen et 89 
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al., 2016) without affecting BP (Chen et al., 2015; Kievit et al., 2013); however, off-target 90 
effects on the melanocortin-1 receptor (skin pigmentation) may limit its wider use. We 91 
hypothesized that a more refined understanding of MC4R signaling and its impact on clinical 92 
phenotypes in the general population may inform the design of drugs targeting this pathway 93 
to treat common obesity and its complications.  94 
 95 
We performed genetic association studies in approximately 0.5 million people from UK 96 
Biobank focusing on 61 nonsynonymous variants identified in MC4R. Twelve of the 61 were 97 
nonsense/frameshift variants; the remainder (n=49) were missense variants whose functional 98 
properties were characterized in cells quantifying canonical Gαs-mediated cAMP production 99 
and the recruitment of β-arrestin to MC4R. In meta-regression analyses using the functional 100 
consequence of MC4R variants as the predictor, we found that 88% of the variance in the 101 
association of different MC4R variants with BMI was explained by their effect on β-arrestin 102 
recruitment. A subset of individuals (6%, n=28,161) were carriers for gain-of-function alleles 103 
that exhibited signaling bias, preferentially increasing β-arrestin recruitment rather than 104 
cAMP production. These individuals had significantly lower BMI (P=2x10-42) and up to 50% 105 
lower risk of obesity, type 2 diabetes and coronary artery disease. Cumulatively, the 106 
characterization of BMI-lowering variants in MC4R demonstrates the pivotal role of β-107 
arrestin-mediated MC4R signaling in human energy homeostasis. These findings have 108 
relevance for the development of β-arrestin-biased MC4R agonists for weight loss and for the 109 
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RESULTS  114 
Genetic variants in MC4R found in the general population cause loss- or gain-of-function in 115 
cells 116 
We studied 61 independent nonsynonymous variants in MC4R (pairwise R2<0.01; variant 117 
allele frequency 2%-0.0001%) that were directly genotyped (n=59) or well-imputed (info 118 
score>0.8; n=2) in 452,300 European ancestry participants from UK Biobank (Methods; Table 119 
S1), which is a UK population-based cohort of people aged 40-69 years (Bycroft et al., 2018; 120 
Sudlow et al., 2015). Of the 61 MC4R variants, 12 were nonsense/frameshift variants and 49 121 
were missense variants (Table S1).  122 
 123 
To characterize the functional consequences of all missense variants in MC4R (Figure 1; Table 124 
S2), HEK293 cells were transiently transfected with constructs encoding Wild-Type (WT) or 125 
mutant MC4Rs. We measured canonical Gαs-mediated signaling by quantifying the maximal 126 
efficacy of ligand (NDP-MSH; melanocyte stimulating hormone)-induced cAMP production 127 
in a time-resolved assay (Figure 1A). Additionally, we quantified the interaction between 128 
WT/mutant MC4R and β-arrestin-2 using a time-resolved enzyme complementation assay 129 
(Figure 1B). We found that 58 of 61 (95%) nonsynonymous MC4R variants had functional 130 
consequences; 47 (77%) resulted in a loss-of-function (LoF), 9 variants (15%) resulted in a 131 
significant gain-of-function (GoF), 2 variants (3%) had opposing effects on the two signaling 132 
pathways and 3 (5%) were wild-type like in both assays (Figure 1A-D; Table S2). In contrast to 133 
most previous studies of human MC4R variants, which have measured the direct/indirect 134 
accumulation of cAMP, we find that the majority of MC4R variants present in UK Biobank 135 
affect both cAMP production and the recruitment of β-arrestin-2 to MC4R.  136 
 137 
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Gain-of-function MC4R variants are associated with protection against obesity and its 138 
metabolic complications 139 
We next performed genetic association studies with a series of primary phenotypes recorded 140 
in UK Biobank: BMI and obesity, hemodynamic phenotypes known to be affected by MC4R 141 
signaling (resting heart rate, systolic and diastolic blood pressure) and risk of type 2 diabetes 142 
and coronary artery disease. We found that LoF variants in MC4R were associated with higher 143 
BMI, and higher odds of obesity, severe obesity, type 2 diabetes and coronary artery disease 144 
(Figure 1E). These results align with reports of LoF MC4R variants identified in cohorts of 145 
obese and severely obese individuals (Farooqi et al., 2003; Hinney et al., 2006; Stutzmann et 146 
al., 2008; Turcot et al., 2018). In contrast, we found that gain-of-function MC4R variants were 147 
strongly associated with lower BMI (P=2x10-47) and lower odds of obesity (P=3x10-38), severe 148 
obesity (P=1x10-09), type 2 diabetes (P=4x10-06) and coronary artery disease (P=0.02) (Figure 149 
1E). GoF, but not LoF variants, were associated with lower diastolic blood pressure and lower 150 
resting heart rate (Table S3).  151 
 152 
Associations with BMI were robust in sensitivity analyses that excluded ultra-rare genetic 153 
variants (variant allele frequency <0.001%) and factored in manually-curated cluster-plot 154 
quality scores (Methods, Table S4). The association of LoF variants with BMI was particularly 155 
strong for variants resulting in protein truncation or complete LoF of either pathway in vitro 156 
(Table S4). For 6 overlapping nonsynonymous variants, associations with BMI were consistent 157 
with external validation data from the GIANT consortium (Locke et al., 2015; Turcot et al., 158 
2018) (Table S4). The association of LoF alleles in MC4R with type 2 diabetes was validated 159 
using exome sequencing data from the T2D Knowledge Portal; odds ratio [OR] for carriers of 160 
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rare LoF variants vs non-carriers, 1.59; 95% confidence interval [CI], 1.22-2.08; P=0.0007; P 161 
heterogeneity compared to the estimate in UK Biobank from this study=0.21. 162 
 163 
β-arrestin-mediated MC4R signaling plays a pivotal role in human weight regulation  164 
We next used random-effects meta-regression to investigate whether β-arrestin recruitment 165 
or cAMP production explained the variance in the association of different MC4R variants with 166 
BMI (Methods; Figure 2). We found that β-arrestin recruitment was a statistically-significant 167 
predictor of the association of different MC4R variants with BMI (P=3×10-05) and explained 168 
88% of the variance in these associations (Figure 2). Several different sensitivity analyses 169 
supported the robustness of this association, including multivariable models with cAMP 170 
production as an additional predictor, leave-one-out analyses excluding one of the variants in 171 
each iteration, models restricted to rare variants (variant allele frequency <0.5%, i.e. 172 
excluding the two variants with the largest weight in the main analysis), models including 173 
nonsense/frameshift variants and models excluding ultra-rare genetic variants and factoring 174 
in manually-curated cluster-plot quality scores  (Methods, Table S5). In contrast, cAMP 175 
production did not predict the associations of different MC4R variants with BMI, either on its 176 
own (P=0.19) or when the degree of β-arrestin recruitment was also included in the model 177 
(P=0.52; Table S5). Increased β-arrestin recruitment also predicted lower estimates of 178 
association with BMI among the 20 variants that were WT-like for cAMP production (P=0.02; 179 
Table S5). Increased β-arrestin recruitment remained a predictor of BMI-associations when 180 
using the functional category (LoF, WT-like or GoF) rather than the actual experimental value 181 
as predictor (P=0.04; Table S5); there was evidence that both LoF and GoF variants 182 
contributed to this association (Table S5). Taken together, these results suggest that β-183 
arrestin-mediated MC4R signaling plays a critical role in the regulation of human body weight. 184 
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  185 
Gain-of-function MC4R variants that preferentially signal through β-arrestin mediate the 186 
protective association with BMI, obesity and its complications 187 
We hypothesized that naturally occurring genetic variants that preferentially affect signaling 188 
through one pathway versus the other (exhibit bias) may provide insights into the 189 
physiological consequences of targeting a specific pathway therapeutically. Among 11 190 
variants resulting in a GoF (including two that were GoF for cAMP but LoF for β -arrestin), five 191 
variants (T11S, T101N, F201L, G231S, R236C) exhibited significant bias  towards cAMP 192 
production, four (V103I, I251L, I289L, I317V) exhibited significant bias towards β -arrestin 193 
recruitment and two (L304F, Y332C) showed no evidence of biased signaling (Figure 3A). GoF 194 
MC4R mutants that led to increased β-arrestin recruitment (but not those that predominantly 195 
increased cAMP production) resulted in enhanced signaling via the Mitogen-Activated Protein 196 
Kinase pathway measured by quantifying Extracellular Signal-Regulated Kinase (ERK1/2) 197 
phosphorylation assayed using Western blotting (Figure 3B-D).  198 
 199 
In UK Biobank, approximately 1 in every 16 participants (6.1%; n=27,750) carried one copy of 200 
a β-arrestin-biased GoF allele, while 1 in every 1,102 (0.1%; n=411) carried two alleles. 201 
Carriers of one GoF allele had a BMI that was on average 0.39 kg/m2 lower than non-carriers  202 
(P=2x10-42; Figure 3E), while carriers of two alleles had a BMI that was 0.88 kg/m2 lower 203 
(P=7x10-05; Figure 3E). The latter is equivalent to ~2.5 kg lower body weight for a person 1.7 204 
metres tall. Carriers of two β-arrestin biased GoF alleles had an approximately 50% lower risk 205 
of obesity (OR, 0.51; P=8x10-06; Fig. 3e), type 2 diabetes (OR, 0.52; P=0.03; Figure 3E) and 206 
coronary artery disease (OR, 0.50; P=0.02; Figure 3E), compared to non-carriers; carriers of 207 
one allele had intermediate risk (Figure 3E). Conversely, carriers of gain-of-function variants 208 
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exhibiting bias towards cAMP production had similar BMIs, and risks of obesity and cardio-209 
metabolic disease as non-carriers; these variants were associated with a significant increase 210 
in systolic and a marginal (but non-significant) increase in diastolic blood pressure compared 211 
to non-carriers (Tables S3 and S6). 212 
 213 
Associations of β-arrestin-biased GoF alleles in MC4R with cardio-metabolic outcomes were 214 
directionally consistent with those observed with a 97-variant polygenic score for lower BMI 215 
derived from a previous genome-wide study (Locke et al., 2015). For coronary artery disease, 216 
per kg/m2 genetically-lower BMI, OR [95% CI] 0.94 [0.93-0.95] for the 97-variant polygenic 217 
score vs 0.82 [0.72-0.95] for the β-arrestin-biased MC4R GoF variants, P heterogeneity = 0.07. 218 
Interestingly, MC4R GoF variants were more strongly associated with a reduced risk of type 2 219 
diabetes (OR [95% CI] per kg/m2 genetically-lower BMI, 0.86 [0.85-0.87] for the 97-variant 220 
polygenic score vs 0.72 [0.62-0.83] for the β-arrestin-biased MC4R GoF variants, P heterogeneity= 221 
0.01). Experimental studies in rodents and humans have shown that impaired MC4R signaling 222 
increases insulin secretion (Fan et al., 2000; Greenfield et al., 2009), which may affect the 223 
onset and prevalence of type 2 diabetes in variant carriers through mechanisms that require 224 
further exploration.  225 
 226 
The most frequent gain-of-function MC4R variant (V103I) leads to increased cell surface 227 
expression of mutant receptors 228 
To explore the potential mechanisms by which increased β-arrestin recruitment leads to a 229 
GoF rather than to a LoF as might be predicted, we studied V103I MC4R, the commonest 230 
nonsynonymous variant (variant allele frequency, 2%) found in UK Biobank which exhibits 231 
significant bias towards β-arrestin-mediated signaling (Figure 3A; P=0.004). Previously, we 232 
Page 11 of 49 
 
and others have reported associations of V103I MC4R with lower BMI and obesity risk (Geller 233 
et al., 2004; Gu et al., 1999; Heid et al., 2005; Stutzmann et al., 2007; Young et al., 2007), 234 
which were confirmed in this analysis (Table S7). In meta-analyses of genetic association 235 
studies including over 600,000 people, we now find that V103I MC4R is associated with lower 236 
risk of type 2 diabetes (P=7×10-07) and of coronary artery disease (P=0.003; Table S7). V103I 237 
MC4R was also associated with lower diastolic blood pressure and resting heart rate, but not 238 
with any adverse disease outcomes in an exploratory phenome-wide association analysis of 239 
353 frequent clinical diagnoses in UK Biobank (Figure S1).  240 
 241 
In contrast to previous studies (Gu et al., 1999; Hinney et al., 2006), we found that V103I 242 
MC4R increased ligand-induced cAMP production in a time-resolved assay (Figure 4A, Figure 243 
S2A and Table S8). β-arrestin recruitment by V103I MC4R was significantly increased in 244 
response to both synthetic and endogenous ligands; an effect that was sustained over 60 245 
minutes (Figure 4B, Figure S2B and Table S8). The magnitude and duration of ligand-induced 246 
ERK1/2 phosphorylation was also increased (P=0.009) (Figure 4C-D, Figure S2C-D). Using 247 
confocal microscopy, we demonstrated that whilst WT MC4Rs translocated from the 248 
membrane into the cytoplasm upon agonist stimulation, V103I MC4R remained at the cell 249 
surface (Figure 4E, Figure S2E). These findings were replicated in a Fluorescence-Activated 250 
Cell Sorting (FACS) assay where cell surface expression of WT MC4R decreased by 23% upon 251 
ligand stimulation (P=0.003; Figure 4F), whilst there was no change in expression of V103I 252 
MC4R (Figure 4F, Figure S2F). Further studies will be needed to investigate whether these 253 
findings may be explained by impaired internalization or accelerated recycling of V103I 254 
MC4Rs leading to an accumulation of V103I MC4R at the cell surface and a gain-of function 255 
(Figure 5). 256 




By combining genetic studies in over 0.5 million people with detailed functional 259 
characterization of identified MC4R variants in cells, we demonstrated that β-arrestin-biased 260 
gain-of-function MC4R variants are associated with lower risk of obesity and its cardio-261 
metabolic complications in the general population. We found that that almost all naturally 262 
occurring nonsynonymous variants in MC4R affect signaling and that the degree of β-arrestin 263 
recruitment to MC4R accounts for a large proportion of the variation in genetic association of 264 
these MC4R variants with BMI in the general population indicating that MC4R signaling 265 
through β-arrestin is critical for its role in the regulation of body weight. Approximately 6% of 266 
European ancestry individuals in the general UK population carry β-arrestin-biased GoF 267 
variants which are associated with up to 50% lower risk of obesity and its metabolic 268 
complications, but are not associated with increased BP and HR. These findings provide strong 269 
human genetic evidence to inform the development of β-arrestin-biased MC4R agonists for 270 
weight loss and the treatment of obesity-associated metabolic disease.  271 
 272 
The discovery of protective human genetic variants  273 
It is well-established that human genetic studies can inform the understanding of disease 274 
mechanisms and the development of new therapeutics. This concept is illustrated by the rapid 275 
development of new lipid-lowering drugs guided by studies of loss-of-function and gain-of-276 
function coding variants in PCSK9 (Cohen et al., 2006), LPA (Clarke et al., 2009), APOC3 (Crosby 277 
et al., 2014; Jorgensen et al., 2014) and ANGPTL3 (Dewey et al., 2017; Musunuru et al., 2010) 278 
and by the higher probability of successful drug development for targets supported by human 279 
genetic evidence (Nelson et al., 2015; Plenge et al., 2013).  280 
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 281 
In addition to studies of genetic variants that cause/are associated with disease/risk of 282 
disease, an alternative approach gaining traction in several fields, is the study of “resilient” 283 
individuals (e.g. smokers who remain healthy) or extremely elderly and healthy individuals 284 
(centenarians) (Friend and Schadt, 2014; Govindaraju et al., 2015; Harper et al., 2015). Several 285 
protective alleles have been identified to date (Liu et al., 1996; Myocardial Infarction Genetics 286 
Consortium et al., 2014). Some of these are rare and ancestry-specific, for example, a LoF 287 
allele within the amyloid-β precursor protein (APP)-coding region in Icelanders reduces 288 
amyloid-β aggregation and may offer protection against Alzheimer’s disease (Goate, 2006). 289 
Scandinavian carriers of variants in SLC30A8 (Solute carrier family 30, member 8) are 290 
significantly less likely to develop type 2 diabetes even if obese (Flannick et al., 2014); 291 
associations that have been replicated in people from other ancestries. However, the 292 
discovery of low frequency variants associated with protection from common complex 293 
diseases is contingent upon sample size, with large numbers of affected individuals and 294 
controls being required to generate sufficient power to detect these associations. Here, by 295 
studying data on BMI and metabolic diseases in 0.5 million participants in UK Biobank and by 296 
focusing on a gene known to be involved in the regulation of weight and harboring a large 297 
number of low frequency variants, we find BMI-lowering genetic variants that are prevalent 298 
in a significant proportion (6%) of European ancestry individuals.  299 
 300 
Our study has demonstrated the value of testing the functional consequences of variants 301 
identified in large scale genetic association studies, in particular as gain-of-function variants 302 
cannot be reliably identified or predicted using in silico algorithms. Here, by measuring the 303 
functional consequences of all missense MC4R variants in cells, we demonstrate strong 304 
Page 14 of 49 
 
associations for gain-of-function variants with lower risk of obesity and show that loss-of-305 
function variants are associated with obesity and diabetes risk in the general population. Loss-306 
of-function MC4R variants were first identified in people with hyperphagia and severe early-307 
onset obesity 20 years ago (Vaisse et al., 1998)(Yeo et al., 1998) and subsequently, over 300 308 
rare variants that reduce cAMP accumulation have been identified, mostly in obese people 309 
(Collet et al., 2017; Stutzmann et al., 2008) (www.mc4r.org.uk). A recent study in the general 310 
population identified an association of the known Y35X/D37V haplotype with higher BMI 311 
(Turcot et al., 2018). However, this and other studies have not detected significant 312 
associations for other MC4R LoF variants with obesity in the general population (Hinney et 313 
al., 2006). We suggest that these discordant findings may be partly explained by the rarity of 314 
these variants but also by the fact that some rare variants, including several predicted 315 
damaging by in silico algorithms, have minimal impact on cAMP signaling but do, as  shown in 316 
this study, impact on β-arrestin recruitment which has previously not been studied. Our study 317 
highlights the value of combining detailed and comprehensive functional characterization of 318 
variants with large-scale genetic analyses. 319 
 320 
While population-based studies may tend to underestimate the phenotypic consequences of 321 
genetic variants, as participants tend to be healthier than individuals in the general population 322 
from which they are sourced, studies of severe clinical cases may overestimate them (Wright 323 
et al., 2019). This may partly explain the smaller impact on BMI for MC4R LoF variants in 324 
population-based cohorts as opposed to cohorts of severely obese people (Farooqi et al., 325 
2003). Furthermore, for a relatively modest difference in BMI (0.4 to 0.9 kg/m2), we observed 326 
that β-arrestin-biased GoF alleles in MC4R were associated with a large difference in risk of 327 
cardio-metabolic disease outcomes (up to 50% lower risk), more than expected from 328 
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observational epidemiology studies (Emerging Risk Factors et al., 2011). This is likely to reflect 329 
the life-long nature of exposure to lower levels of the risk factor (BMI) due to genotype, as 330 
opposed to short-term exposure in observational studies or clinical trials. Typical examples of 331 
this phenomenon are genetic variants associated with small differences in low-density-332 
lipoprotein cholesterol that are associated with a large reduction in cardiovascular risk (Cohen 333 
et al., 2006; Ference et al., 2015).  334 
 335 
Insights into biased signaling from human variants in GPCRs  336 
With advances in GPCR biology and in our understanding of structure activity relationships 337 
(Whalen et al., 2011), the potential to develop biased agonists that differentially activate 338 
signaling pathways is beginning to be realized. Experiments demonstrating that morphine has 339 
greater analgesic properties and causes less respiratory depression and constipation in β-340 
arrestin-2 knockout mice have paved the way for trials of a small-molecule mu-opioid 341 
receptor agonist which stimulates nearly undetectable levels of β-arrestin recruitment 342 
compared to morphine (Wadman, 2017). However, cell-type specific effects on the 343 
differential propagation of signaling responses can affect the interpretation of 344 
pharmacological studies resulting in a need to establish which signaling pathway leads to the 345 
desired therapeutic effect in vivo (Gundry et al., 2017). By demonstrating that gain-of-346 
function β-arrestin-biased MC4R alleles in the population are associated with up to a 50% 347 
lower risk of obesity and type 2 diabetes, our studies demonstrate that naturally occurring 348 
genetic variants in a GPCR can be used to characterize the physiological consequences of 349 
biased signaling in humans. This approach is likely to have broader relevance. By analyzing 350 
data from over 68,000 individuals, Hauser et al. have recently shown that there is substantial 351 
variation in genes encoding 108 GPCRs that are targeted by known drugs (Hauser et al., 2018). 352 
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Combining genetic predictions with experiments in cells, they showed that specific variants 353 
in the mu-opioid and Cholecystokinin-A receptors could affect therapeutic responses invitro 354 
which they hypothesized might predict clinical response in vivo. Our data suggests that the 355 
phenotypic consequences of genetic variants that exhibit natural signaling bias for a given 356 
pathway may serve as a “blueprint” for the likely consequences of preferentially modulating 357 
that pathway pharmacologically with a biased agonist. This approach may be generalizable to 358 
other GPCRs and thus to the development of a broad spectrum of drug targets.  359 
 360 
In summary, our work has shown that dissecting the molecular mechanisms underpinning 361 
genetic associations with disease, and with protection from disease, can advance our 362 
understanding of how to most effectively target specific GPCRs for the treatment of common 363 
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MAIN FIGURE TITLES AND LEGENDS 395 
Figure 1. Gain-of-function MC4R variants are associated with protection from obesity and 396 
its complications. (A) Maximal efficacy of NDP-MSH-induced cAMP production and (B) β-397 
arrestin recruitment for mutant MC4Rs. Data represented as mean (95% CI) of 4-12 398 
independent experiments; each mutant expressed as % WT. Variants classified as Gain-of-399 
Function (GoF) (orange), Loss-of-Function (LoF) (blue) or WT-like (grey) based on statistically 400 
significant differences between WT and mutant (unpaired single-sample t-test). (C) MC4R 401 
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protein highlighting amino acids affected by variants. *†Residues affected by >1 variant; 402 
*R165W (LoF) and R165Q (LoF); †G231S (GoF) and G231V (WT-like). (D) Counts for GoF (n=9) 403 
and LoF (n=47) variants included in genetic association analyses. Five variants with opposite 404 
effects in the two assays or WT-like results were excluded. (E) Genetic associations of GoF 405 
and LoF MC4R variants with BMI, obesity and its complications. OR, odds ratio; CI, confidence 406 
interval; BMI, body mass index, n, number of participants. See also Tables S1-S4.  407 
 408 
Figure 2. β-arrestin recruitment by different MC4R variants explains a significant proportion 409 
of the variance in their association with BMI. Model (top) and results (bottom) from a meta-410 
regression analysis in which β-arrestin recruitment for each MC4R mutant was the predictor 411 
and association estimates for BMI were the outcome. Circles represent each variant, wi th 412 
circle size proportional to the weight of each variant in the model. The enlarged box shows 413 
the area where variants with the largest weight clustered. CI, confidence interval; BMI, body 414 
mass index. Sensitivity analyses excluding the two variants with the largest weight and leave-415 
one-out analyses are in Table S5.  416 
 417 
Figure 3. Gain-of-Function MC4R variants that exhibit bias towards β-arrestin-mediated 418 
signaling protect against obesity and its complications. (A)  Signaling bias for 11 GoF MC4R 419 
mutants calculated as ratio (95% CI) of geometric means for maximal activity of β -arrestin to 420 
cAMP; data from 4-12 experiments. The null hypothesis of no bias (ratio=1) was tested using 421 
unpaired two-sample t-test. Variants were classified as biased towards β-arrestin (green), 422 
cAMP (purple) or unbiased (grey). (B) Representative Western blots and (C) quantification of 423 
ERK1/2 phosphorylation (expressed as % WT) before (-) and after (+) NDP-MSH stimulation 424 
of GoF MC4R mutants; Epidermal Growth Factor [EGF] used as a positive control; vinculin as 425 
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a loading control. Data represented as mean ± SEM from 3-8 independent experiments ; 426 
statistical significance of differences between WT and mutant (unpaired single-sample t-test). 427 
(D)  Meta-regression analysis showing that greater bias for β-arrestin recruitment predicts 428 
greater ERK1/2 phosphorylation for GoF variants (depicted as circles with size proportional to 429 
precision in ERK1/2 phosphorylation estimates). (E) Associations with BMI (Body Mass Index), 430 
obesity, severe obesity, type 2 diabetes, coronary artery disease, resting heart rate (RHR) in 431 
beats/minute (bpm), systolic and diastolic blood pressure (SBP and DBP) in millimetres of 432 
mercury (mmHg) by carrier status for β-arrestin biased GoF MC4R alleles. OR, odds ratio; CI, 433 
confidence interval; IQR, interquartile range, n, number of participants. See also Tables S6 434 
and S7.  435 
 436 
Figure 4.  Effects of V103I MC4R on signaling and receptor internalization. Dose response 437 
curves for MSH, MSH and NDP-MSH-induced (A) cAMP production and (B) β-arrestin 438 
recruitment for V103I compared to WT MC4R and mock transfected cells; expressed as % WT. 439 
Data represented as mean ± SEM from 4 independent experiments. Representative Western 440 
blots and quantification of ERK1/2 phosphorylation by WT and V103I MC4R before (-) and 441 
after (+) stimulation by (C) MSH and MSH and (D) NDP-MSH in a time-course experiment; 442 
Epidermal Growth Factor [EGF] used as a positive control; vinculin as a loading control. (E)  443 
Confocal microscopy and (F) receptor internalization quantified by FACS for cells expressing 444 
WT and V103I MC4R before (-) and after (+) stimulation by NDP-αMSH. Scale bars, 50 m; 10 445 
m (inset). Data represented as mean ± SEM from 3-8 independent experiments; statistical 446 
significance of differences between WT and mutant analyzed with unpaired single-sample t-447 
test (A, B, C, D, F); *p < 0.05; **p < 0.01. AUC; area under the curve. See also Figures S1 and 448 
2 and Table S8. 449 
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 450 
Figure 5.  Mechanisms by which V103I MC4R causes a gain-of-function. Schematic of 451 
mechanisms by which V103I MC4R (pink dot) results in GoF; G proteins (α,β,γ); MSH, 452 
melanocyte stimulating hormone; AC, adenylate cyclase; CRE, cyclic AMP response element; 453 
TF, transcription factor.  454 
 455 
 456 
SUPPLEMENTAL FIGURE TITLES AND LEGENDS 457 
 458 
Figure S1. Phenome-wide scan of the associations of V103I MC4R with 353 common 459 
diagnoses. Analyses were performed in European ancestry participants of UK Biobank. Only 460 
diagnosis codes with >500 cases were included. Diagnosis codes were grouped in 19 broad 461 
categories. Each triangle represents the association for a given diagnosis code. Full triangles 462 
that are upward-pointing represent associations in a risk increasing direction, while open 463 
triangles that are downward-pointing represent associations in a protective direction. The 464 
horizontal broken line represents the statistical significance threshold of P<0.00014, 465 
corresponding to a Bonferroni correction for 353 diagnoses. Related to Figure 4. 466 
 467 
Figure S2. Effects of V103I MC4R on cAMP production,  -arrestin recruitment, MAPK 468 
pathway activation and cell surface expression. Representative real-time measurement of 469 
(A) cAMP (B) -arrestin recruitment upon NDP-MSH stimulation. (C) Time-course 470 
quantification and (D) respective area under the curve (AUC) of ERK1/2 phosphorylation 471 
assessed by Homogenous Time-Resolved Resonance Energy Transfer (HTRF)-based sandwich 472 
immunoassay (Cisbio, 64AERPET); data expressed as % WT. WT (open squares), V103I (solid 473 
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squares) MC4R; mean ± standard error; (n=4); statistical significance of differences between 474 
WT and mutant analyzed in an unpaired single-sample t-test; **p < 0.01. (E) Confocal 475 
microscopy on COS-7 cells expressing WT and V103I MC4R unstimulated and upon NDP-αMSH 476 
stimulation. MC4R in red (Anti-FLAG (M2) antibody), plasma membrane in green (wheat germ 477 
agglutinin) and nuclei in blue (DAPI). Scale bars, 50 μm. (F) Effects of V103I MC4R on receptor 478 
internalization quantified by FACS. Representative data on receptor internalization using HeLa 479 
cells transiently transfected with FLAG-MC4R WT or V103I. Mock-transfected cells were used 480 
as controls for non-specific binding of the antibody (FLAG-PE; negative control). Mean 481 
fluorescence intensity (MFI) represents the amount of MC4R present at the cell surface; 482 
receptor internalization was quantified using the mean fluorescence intensity (MFI) values of 483 
FLAG-PE+ cells from unstimulated (-) and NDP-αMSH stimulated WT and V103I MC4R. Related 484 
to Figure 4. 485 
 486 
STAR METHODS 487 
CONTACT FOR REAGENT AND RESOURCE SHARING 488 
Further information and requests for resources and reagents should be directed to and will 489 
be fulfilled by the Lead Contact, Sadaf Farooqi (isf20@cam.ac.uk). 490 
 491 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 492 
Studies in humans 493 
UK Biobank is a prospective population-based cohort study of people aged 40-69 years who 494 
were recruited in 2006-2010 from 22 centres located in urban and rural areas across the 495 
United Kingdom (Sudlow et al., 2015). Participants’ characteristics are reported in Table S1. 496 
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UK Biobank has received ethical approval from the North West Multicentre Research Ethics 497 
Committee and participants gave written informed consent. 498 
 499 
Studies in cellular models 500 
HEK293 (XX female) and suspension HeLa (XX female) cells were cultured in high glucose 501 
Dulbecco's modified eagle medium (DMEM, Gibco, 41965) and supplemented with 10% fetal 502 
bovine serum (Gibco, 10270, South America origin), 1% GlutaMAXTM (100X) (Gibco, 35050), 503 
and 100 units/mL penicillin and 100 μg/mL streptomycin (Sigma-Aldrich, P0781). Cells were 504 
incubated at 37⁰C in humidified air containing 5% CO2 and transfections were performed 505 
using Lipofectamine 2000™ (Gibco, 11668) in serum-free Opti-MEM I medium (Gibco, 31985) 506 
according to the manufacturer’s protocols. 507 
 508 
  509 
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METHOD DETAILS 510 
STUDIES IN HUMANS 511 
Genotype data 512 
We studied 61 nonsynonymous genetic variants in MC4R (NCBI Reference NM_005912) that 513 
were directly genotyped or well-imputed in UK Biobank (Table S1). All participants of UK 514 
Biobank with suitable DNA samples underwent genome-wide SNP-array genotyping using the 515 
Affymetrix UK BILEVE and UK Biobank Axiom arrays, with imputation to the Haplotype 516 
Reference Consortium r1.1 panel (McCarthy et al., 2016) supplemented with the 1000 517 
Genomes phase 3 (Altshuler et al., 2015) and UK10K (Walter et al., 2015) panels, as previously 518 
described. (Bycroft et al., 2018). A total of 59 variants were directly genotyped, while 2 genetic 519 
variants were imputed and had an imputation quality score greater than 0.8, indicating high-520 
quality imputation. The 61 variants included in this study had pairwise R2<0.01, consistent 521 
with no or negligible linkage disequilibrium. 522 
 523 
Genotype quality checks 524 
Genotype quality control in UK Biobank followed guidelines that have been published in detail 525 
elsewhere (Bycroft et al., 2018). In brief, DNA samples were assigned to genotype batch using 526 
an automated sample selection algorithm to ensure random assignment relative to baseline 527 
characteristics. Genotyping underwent a number of quality control procedures including (a) 528 
routine quality checks carried out during the process of sample retrieval, DNA extraction, and 529 
genotype calling; (b) checks and filters for genotype batch effects, plate effects, departures 530 
from Hardy-Weinberg equilibrium, sex effects, array effects, and discordance across control 531 
replicates; (c) individual and genetic variant call rate filters. Wright et al. (Wright et al., 2019) 532 
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have proposed that the expert manual review of genotype cluster plots may help distinguish 533 
lower vs higher quality genotyped variants in UK Biobank, particularly for rare alleles. We 534 
adopted a similar scoring approach. In the aforementioned study, cluster plots for each 535 
genotyping-batch were merged into one single cluster plot. In this study, instead, we 536 
reviewed cluster-plots by genotyping-batch, which reflects the data units parsed by the 537 
genotyping algorithm and is less likely to be influenced by batch effects or variation in 538 
fluorescence signal. Cluster plots were generated using evoker-lite 539 
(https://github.com/dlrice/evoker-lite) using the default configuration for UK Biobank data. 540 
This plots the clusters in the groupings and on the axes that are used by the clustering 541 
algorithm. Each variant is plotted for each genotyping batch separately, using x axis (contrast 542 
between signals A and B) = log2(A/B), and Y axis (signal strength) = log2(A*B)/2. Two 543 
independent expert laboratory team members reviewed the cluster plots of each batch for 544 
each of the rare variants in MC4R included in the study. Blind to each other and to the 545 
association results, they scored the cluster-plot quality of each variant as low (score=0, most 546 
cluster plots display low-quality, defined for instance by carriers being called at the edge of a 547 
the cluster of non-carriers without contrast separation or with very low signal strength), 548 
intermediate (score=1, the majority of cluster plots display high quality, defined by separation 549 
of clusters and signal strength of carriers close to average) or high (score=2, all or almost all 550 
cluster plots display high-quality). Individual scoring was highly consistent with ~80% of 551 
variants receiving the same exact score and only 1 variant receiving a high-score by one scorer 552 
and a low-score by the second scorer (resolved with scoring by a third independent scorer). 553 
The results of the individual scoring were summed into an overall cluster-plot quality score 554 
and variants defined as low-quality cluster plot score if the combined score was 0 or 1, 555 
intermediate-quality if the combined score was 2, high-quality if the combined score was 3 or 556 
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4. One variant had a low-quality cluster-plot score (V166I), while two had intermediate-557 
quality scores (G55D and F202L) and all other variants had high quality cluster-plot scores.  558 
 559 
Genetic association analysis 560 
Association of genotypes with outcome phenotypes were estimated using linear or logistic 561 
regression models, as appropriate for outcome type and analytical design. To minimize 562 
genetic confounding, association analyses were restricted to European ancestry individuals, 563 
identified by combining k-means clustering of genetic principal components with self-564 
reported ancestry. To control for relatedness, analyses were either clustered using family 565 
structure data (third degree relatives) and adjusted for 40 genetic principal components or 566 
performed using linear mixed-effects models adjusting for a genomic kinship matrix. All 567 
analyses were adjusted for age, sex and genotyping array. 568 
 569 
In analyses of the association of GoF or LoF variants, association estimates for each variant of 570 
either functional category were pooled using fixed-effect inverse-variance weighted meta-571 
analysis (Burgess et al., 2013). In these analyses, GoF variants were variants with significantly 572 
enhanced cAMP production or β-arrestin recruitment compared to wild-type MC4R in 573 
experiments. LoF variants were variants with significantly reduced cAMP production or β -574 
arrestin recruitment compared to wild-type MC4R or variants resulting in premature receptor 575 
truncation (frameshift or nonsense variants). Variants that were WT-like or had opposite 576 
effects on the two pathways (GoF for cAMP production but LoF for β-arrestin recruitment) 577 
were excluded from these analyses. Genetic association analyses were performed using 578 
STATA v14.2 (StataCorp, College Station, Texas 77845 USA), R v3.2.2 (The R Foundation for 579 
Statistical Computing), BOLT-LMM v2.3.2 (Loh et al., 2018; Loh et al., 2015).  580 
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 581 
Phenotype definitions 582 
Primary outcomes of interest were BMI, obesity, type 2 diabetes and coronary artery disease. 583 
We also investigated associations with hemodynamic phenotypes known to be affected by 584 
MC4R signaling (Greenfield et al., 2009), i.e. resting heart rate, systolic and diastolic blood 585 
pressure. BMI was calculated as weight in kilograms divided by height in meters squared. 586 
Height was measured using a Seca 240cm tape, while weight was measured using a Tanita 587 
BC418MA body composition analyzer. Systolic, diastolic blood pressure and resting heart rate 588 
were measured at baseline using an Omron blood pressure monitor and following a 589 
standardized procedure (http://biobank.ctsu.ox.ac.uk/crystal/docs/Bloodpressure.pdf). Type 590 
2 diabetes was defined on the basis of self-reported physician diagnosis at nurse interview or 591 
digital questionnaire, age at diagnosis older than 36 years (to exclude likely type 1 diabetes 592 
cases), use of oral anti-diabetic medications or electronic records of hospital admissions or 593 
death reporting type 2 diabetes as diagnosis or cause of death (International Statistical 594 
Classification of Diseases and Related Health Problems Tenth Revision [ICD-10] code E11). 595 
Coronary artery disease was defined as either (a) myocardial infarction or coronary disease 596 
documented in the participant’s medical history at the time of enrolment by a trained nurse 597 
or (b) hospitalization or death involving acute myocardial infarction or its complications (i.e. 598 
ICD-10 codes I21, I22 or I23). Obesity was defined on the basis of BMI greater than or equal 599 
to 30 kg/m2 and severe obesity as BMI greater than or equal to 40 kg/m2. In obesity 600 
association analyses, the control group was the group of people with BMI less than 25 kg/m2. 601 
 602 
Meta-regression 603 
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The potential for in vitro measures of β-arrestin recruitment or cAMP production to explain 604 
the variance (i.e. between-genetic-variants variance) in the association of different MC4R 605 
genetic variants with BMI was investigated using random-effects meta-regression. In these 606 
models, the predictors were the relative Emax for β-arrestin recruitment and/or cAMP 607 
signaling of a given MC4R variant allele compared to wild-type (on a natural log-scale) 608 
measured in vitro as described below. Values of the outcome were the associations of each 609 
genetic variant with BMI (in kg/m2 per copy of variant allele), estimated in 450,708 European 610 
ancestry participants in UK Biobank using linear mixed models adjusted for age, sex and a 611 
genomic kinship matrix. For significant predictors, the percentage of total variance in the 612 
outcome explained by a given predictor (e.g. in vitro β-arrestin recruitment) was calculated.  613 
Similar meta-regression analyses were conducted (1) in the overall set of 49 missense variants 614 
using the functional category of β-arrestin recruitment (ie. LoF, WT-like or GoF) to assess 615 
whether the different functional categories of genetic variants predicted their association 616 
with BMI; (2) in a subset of 20 missense variants that were found to be wild-type-like for cAMP 617 
signaling to assess whether in vitro β-arrestin recruitment predicted their association with 618 
BMI; and (3) in a subset of 11 gain-of-function variants to assess whether bias towards β-619 
arrestin recruitment in vitro predicted their level of signaling via the ERK/MAPK pathway. 620 
 621 
Sensitivity and external validation analyses 622 
Associations with BMI of functional variants in MC4R: To assess whether genotyping cluster-623 
plot quality was influencing associations with BMI, we conducted sensitivity analyses after (a) 624 
exclusion of ultra-rare genetic variants (variant allele frequency < 0.001%; ie. variants that 625 
were shown to have generally lower quality cluster-plot scores by Wright et al. (Wright et al., 626 
2019); (b) exclusion of variants from point (a) plus any variant with low overall cluster-plot 627 
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quality score; (c) exclusion of variants from points (a-b) plus any variant with intermediate  628 
cluster-plot quality score; (d) exclusion of variants from points (a-c) plus any variant where 629 
the combined cluster-plot quality score was below 4 (ie. the maximum possible score). 630 
 631 
Meta-regression analyses: The main analysis (Figure 2) included all 49 missense variants in 632 
MC4R found in European ancestry participants of UK Biobank. Over 50 sensitivity analyses 633 
were conducted to assess the robustness of the results of the main analysis (Table S5). First, 634 
we conducted 49 leave-one-out analyses where each missense variant was excluded at a 635 
given iteration to assess if a single variant was driving the association observed in the main 636 
analysis. Then, we conducted an analysis of rare variants only (i.e. excluding the low-637 
frequency V103I and I251L variants, which had the largest weight in the main analysis) to 638 
assess whether V103I and I251L were driving the association. Then, we conducted a 639 
multivariable analysis in which both in vitro β-arrestin recruitment and in vitro cAMP signaling 640 
were included in the model as possible predictors, to assess whether in vitro β-arrestin 641 
recruitment was an independent predictor from cAMP signaling. Then, we conducted an 642 
analysis including all 61 nonsynonymous genetic variants in MC4R found in European ancestry 643 
participants of UK Biobank, to assess whether the association was influenced by the focus of 644 
our main analysis on missense variants directly expressed in vitro. For this analysis, the level 645 
of β-arrestin recruitment of nonsense/frameshift variants of MC4R was assumed to be 1% of 646 
wild-type. Finally, to assess whether genotyping cluster-plot quality was influencing the 647 
association, we conducted analyses after (a) exclusion of ultra-rare genetic variants (variant 648 
allele frequency < 0.001%); (b) exclusion of variants from point (a) plus any variant with low 649 
overall cluster-plot quality score; (c) exclusion of variants from points (a-b) plus any variant 650 
with intermediate cluster-plot quality score; (d) exclusion of variants from points (a-c) plus 651 
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any variant where the combined cluster-plot quality score was below 4 (ie. the maximum 652 
possible score). 653 
 654 
External validation: We attempted to validate genetic associations using available external 655 
datasets. For 6 overlapping nonsynonymous variants in MC4R, we meta-analyses our BMI-656 
association results with those from up to 550,000 participants in the GIANT consortium (Locke 657 
et al., 2015; Turcot et al., 2018). We also used publically-accessible data from exome 658 
sequencing of 9121 type 2 diabetes cases and 9335 controls from the T2D Knowledge portal 659 
(URL: http://www.type2diabetesgenetics.org/ accessed 15th February 2019) to test the 660 
association between LoF variants in MC4R and type 2 diabetes.  661 
  662 
Additional genetic association analyses for the V103I MC4R variant 663 
The association of the V103I MC4R gain-of-function variant with risk of type 2 diabetes and 664 
coronary artery disease was estimated in meta-analyses of large-scale genetic association 665 
studies. The type 2 diabetes association meta-analysis included 68,906 cases and 551,079 666 
controls from the DIAGRAM (Morris et al., 2012), EPIC-InterAct (InterAct et al., 2011) and UK 667 
Biobank (Sudlow et al., 2015) studies. The coronary artery disease association meta-analysis 668 
included 85,697 cases and 550,908 controls from the CARDIoGRAMplusC4D (Nikpay et al., 669 
2015) and UK Biobank (Sudlow et al., 2015) studies. Association estimates from each study 670 
were combined fixed-effect inverse-variance weighted meta-analysis, as done previously with 671 
similar data sources (Lotta et al., 2016). 672 
 673 
We also conducted a phenome-wide analysis of the association of the V103I MC4R variant 674 
with 353 clinical diagnoses using electronic health records from European ancestry 675 
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participants of UK Biobank. Diagnoses were defined on the basis of the first three digits of 676 
ICD-10 entry codes (for instance, “F20” for a diagnosis of schizophrenia). For a given diagnosis, 677 
we considered individuals as cases if the code corresponding to the diagnosis was entered as 678 
primary or secondary diagnosis in any of their hospital admission records or as a primary or 679 
secondary cause of death in their death certificate. Individuals without the code served as 680 
controls. To minimize the burden of multiple testing and reduce the risk of false positives, we 681 
(a) considered only diagnoses with a total number of cases greater than 500, and (b) used a 682 
Bonferroni corrected p<0.00014 (corresponding to 0.05/353) as statistical significance 683 
threshold. 684 
 685 
STUDIES IN CELLULAR MODELS 686 
Functional characterization of human variants 687 
 688 
Cloning and site-directed mutagenesis 689 
MC4R cDNA constructs containing an N-terminal FLAG tag in pCDNA3.1(+) vector (Invitrogen) 690 
were used throughout the study. Site-directed mutagenesis was performed using QuikChange 691 
II XL kit (Agilent Technologies, 200516) according to the manufacturer’s protocols. All 692 
constructs were verified with Sanger sequencing. In order to characterize the functional 693 
consequences of MC4R mutants we performed assays in transiently transfected HEK293 694 
(ATCC) and suspension HeLa cells, kindly provided by Dr Kevin Moreau (University of 695 
Cambridge). 696 
 697 
Time-resolved cAMP measurement assay 698 
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Measurement of ligand-induced cAMP generation in HEK293 cells transiently expressing 699 
WT/mutant MC4R was performed using the GloSensorTM cAMP biosensor (Promega) 700 
according to manufacturer’s protocols. Briefly, 40,000 cells were seeded in white 96-well 701 
poly-D-lysine-coated plates. After 24 hours, cells were then transfected with both 100 ng/well 702 
of pGloSensorTM-20F cAMP plasmid (Promega, E1171) and 30 ng/well of plasmid encoding 703 
either WT/mutant MC4R. The day after transfection, cell media were replaced by 90 l of 704 
fresh full DMEM with 2% v/v GloSensorTM cAMP Reagent (Promega, E1290) and incubated for 705 
120 min at 37°C. Firefly luciferase activity was measured at 37⁰C and 5% CO2 using Spark 10M 706 
microplate reader (Tecan). After initial measurement of the baseline signal for 10 min (1 707 
minute intervals), cells were stimulated with 10 l of 10x stock solution of the MC4R agonist 708 
NDP-MSH (final concentration 1 M) and real-time chemiluminescent signal was quantified 709 
for 45 minutes (30 seconds intervals). In each experiment, a negative control using mock 710 
transfected cells (empty pcDNA3.1(+) plasmid) and a positive control where cells were 711 
stimulated with 10 M forskolin were assayed. The area under the curve (AUC) for cAMP 712 
production was calculated for each MC4R mutant using the baseline signal and the total peak 713 
of each curve. For data normalization, the AUC from mock transfected cells was set as 0% and 714 
the AUC from WT MC4R was set as 100%. Results represent 4-12 independent experiments. 715 
For V103I MC4R, dose-response curves using NDP-MSH, MSH and MSH were plotted 716 
from total peak area under the curve values calculated for each agonist concentration, 717 
ranging from 10-11 to 10-6 M. Then, sigmoidal dose-response curves with variable slope (three-718 
parameter logistic regression) were plotted. Normalized data were merged and presented as 719 
sum curves.  Results are from 4 independent experiments. 720 
 721 
Time-resolved  -arrestin recruitment assay 722 
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Coupling between MC4R and β-arrestin 2 was monitored using a NanoBiT™ protein: protein 723 
interaction assay (Promega®, M2014). WT/mutant MC4Rs were cloned into pBiT1.1-C 724 
[TK/LgBiT] vector and β-arrestin 2 into pBiT2.1-N [TK/SmBiT] vector. Assays were performed 725 
in HEK293 cells seeded in poly-D-lysine-coated, white 96-well plates (40,000 cells/well) 726 
transiently transfected with 50 ng/well of each of the two constructs as specified previously.  727 
For the negative control, SmBiT-β-arrestin 2 construct was substituted with NanoBiT™ 728 
negative control vector (HaloTag-SmBiT). Positive control consisted of SmBiT-PRKACA and 729 
LgBiT-PRKAR2A vectors. Following transfection, cells were maintained overnight in cell 730 
culture medium as specified previously. The next day, 30 minutes prior to the assay, culture 731 
medium was substituted for 100 μl/well serum-free Opti-MEM I medium (Gibco, 31985). 732 
Nano-luciferase activity was measured at 37⁰C and 5% CO2 using Spark 10M microplate reader 733 
(Tecan). After initial measurement of the background signal, 25 μl/well Nano-Glo® Live Cell 734 
Assay System (Promega®, N2013) was added and cells were equilibrated while basal luciferase 735 
activity was measured for 10 minutes (1 minute intervals). Subsequently, cells were 736 
stimulated with 10 l of 13.5x stock solution of the MC4R agonist NDP-MSH (final 737 
concentration 1 M), and chemiluminescent signal was quantified for 45 minutes (30 seconds 738 
intervals). The area under the curve (AUC) was calculated for each MC4R mutant using the 739 
average value for the negative control as the baseline and the total peak of each curve. For 740 
data normalization, the AUC from the negative control was set as 0% and the AUC from WT 741 
MC4R was set as 100%. Results are from 4-11 independent experiments. For V103I MC4R, 742 
dose-response curves using NDP-MSH, MSH and MSH were plotted from total peak area 743 
under the curve values calculated for each agonist concentration, ranging from 10 -11 to 10-6 744 
M. Then, sigmoidal dose-response curves with variable slope (three-parameter logistic 745 
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regression) were plotted. Normalized data were merged and presented as sum curves. Results 746 
are from 3-5 independent experiments. 747 
 748 
Western-blotting 749 
For these experiments, 1.5 x105 HEK293 cells were seeded in a poly-D-lysine coated 24-well 750 
plate and transfected the next day, when cells had reached 80% confluency, with 250 ng of 751 
MC4R constructs. Cells were serum starved overnight and stimulated for indicated periods of 752 
time with either NDP-MSH (1 M), MSH (1 M) or MSH (1 M). Additional stimulation 753 
with recombinant human epidermal growth factor (EGF, 10 ng/mL, Invitrogen, PHG0311, 5 754 
minutes) was also performed as a positive control. Then, cells were washed once with PBS 755 
and lysed in radio-immunoprecipitation assay buffer (RIPA) (Sigma, R0278) supplemented 756 
with protease and phosphatase inhibitors (Roche cOmplete™, Mini Protease Inhibitor 757 
Cocktail, 11836153001; Roche PhosSTOP™, PHOSS-RO). After being harvested from the wells 758 
and centrifuged at 14,000 rpm for 15 minutes, the samples were prepared for electrophoresis  759 
(resuspended in 1x Bolt™ LDS sample buffer (Thermo, B0007) and 1x Bolt™ reducing agent 760 
(Thermo, B0009) and heated for 10 minutes at 85C). Equal amounts of protein were used 761 
and protein electrophoresis was performed using Bolt™ 4-12% Bis-Tris Plus gels (Thermo, 762 
NW04125BOX) and transfered onto nitrocellulose membrane using an iBLOT™ (Thermo, 763 
IB301001). After blocking with 5% bovine serum albumin (BSA) solution in Tris -buffered saline 764 
(TBS) supplemented with 0.1% Tween® 20 (TBS-T) for 1 hour at room temperature, 765 
membranes were probed overnight at 4οC using a Rabbit anti-p44/42 mitogen-activated 766 
protein kinase (MAPK) (extracellular signal–regulated kinases, Erk1/2) (137F5) at 1:1000 767 
dilution (Cell Signaling Technology, 4695), a Rabbit anti-Phospho-p44/42 MAPK (Erk1/2) 768 
(Thr202/Tyr204) at 1:1000 dilution (Cell Signaling Technology, 9101) or a Rabbit-Anti-Vinculin 769 
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[EPR8185] at 1:5000 dilution (Abcam, ab129002), all prepared in the blocking buffer. Cells  770 
were washed three times with TBS-T for 10 minutes at room temperature with gentle shaking. 771 
They were then incubated with secondary antibody, Goat anti-rabbit IgG-HRP (Dako, P0448) 772 
diluted 1:2500 in 2% BSA in TBS-T for 1 hour at room temperature. Bands were developed 773 
using enhanced chemiluminescence (ECL) substrate (Promega, W1015) and images were 774 
captured with an ImageQuant LAS 4000 (GE Healthcare). The band intensity of Western blots 775 
was quantified using FIJI (Schindelin et al., 2012). For data normalization, unstimulated WT 776 
MC4R readouts were set as baseline (0%), and maximum WT MC4R ERK1/2 phosphorylation 777 
upon agonist stimulation was set as 100%. ERK1/2 phosphorylation data was plotted as 778 
pERK1/2/ tERK1/2. Results are from three to eight independent experiments.  779 
 780 
ELISA for cell surface expression 781 
Relative cell surface expression of MC4R mutants was assessed in transiently transfected 782 
HEK293 cells. 40,000 cells/well in a clear 96-well plates coated with poly-D-lysine and 783 
transfected the following day (30 ng cDNA/well). 24 hours after transfection, cells were fixed 784 
with 3.7% paraformaldehyde (15 minutes) at room temperature (RT) and washed three times 785 
with phosphate-buffered saline (PBS). Subsequently, non-specific binding sites were blocked 786 
with 3% non-fat dry milk in 50 mM Tris-PBS pH 7.4 (blocking buffer) for 1 hour at RT. Next, 787 
cells were incubated with a mouse monoclonal anti-FLAG (M2) antibody (Sigma-Aldrich, 788 
F1804) (dilution 1:1000 in blocking buffer) overnight at 4°C followed by triple washing with 789 
PBS and incubation with polyclonal goat anti-mouse immunoglobulins conjugated with 790 
horseradish peroxidase (HRP) (Dako, P0447) (1:1250 in 1.5% non-fat dry milk in 50 mM Tris-791 
PBS pH 7.4) for 2 hours at RT. Finally, plates were washed three times with PBS and the high 792 
performance chromogenic substrate 3,3´,5,5´̵tetramethylbenzidine (TMB CORE+, Bio-Rad 793 
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Laboratories, BUF062) was used to detect HRP activity. The reaction was terminated with 0.2 794 
M H2SO4. Color reaction product was transferred to another 96-well plate prior to 795 
measurement of absorbance at 450 nm using Infinite M1000 PRO microplate reader (Tecan®). 796 
Six technical replicates were performed for each mutant in a given assay. Data were 797 
normalized to mean absorbance for pcDNA3.1(+) mock-transfected cells. Results are from 798 
four independent experiments. Statistical significance of differences between WT and mutant 799 
were estimated by unpaired t-test. 800 
 801 
Confocal Microscopy 802 
150,000 HEK293 cells were seeded onto glass coverslips in 12-well plates and transfected with 803 
250 ng of FLAG-tagged MC4R constructs. 24 h after transfection, cells were serum starved for 804 
2 h and then stimulated for 15 minutes with NDP-MSH (1 M) at 37C. Cells were then fixed 805 
with 4% formaldehyde in PBS for 10 minutes at room temperature and washed three times 806 
for 5 minutes with phosphate-buffered saline (PBS). After permeabilization with 0.1% Triton™ 807 
X-100 in PBS for 5 minutes, cells were incubated with phycoerythrin (PE)-conjugated anti-808 
DYKDDDDK tag antibody, clone L5 (Biolegend, 637310) diluted 1:100 in blocking buffer. Slides 809 
were imaged using a Leica SP8 confocal microscope and images processed using FIJI. Results 810 
are from three independent experiments. 811 
 812 
Fluorescence-activated cell sorting (FACS) 813 
80,000 suspension HeLa cells were seeded in 6-well CytoOne plates (USA Scientific, CC7672-814 
7506) and transfected with 250 ng of FLAG-tagged MC4R constructs. 24 hours after 815 
transfection, cells were serum starved for 2 hours and then stimulated for 15 minutes with 816 
NDP-MSH (1 M) at 37C. Cells were washed once with serum-free medium, high glucose 817 
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DMEM, no phenol red (DMEM, Gibco, 31053), followed by fixation with 4% formaldehyde in 818 
PBS for 10 minutes at room temperature. After washing three times with PBS, cells were 819 
incubated at 4C for 30 minutes with PE-conjugated anti-DYKDDDDK tag antibody, clone L5 820 
(Biolegend, 637310) diluted 1:100 in serum-free medium. After an extra wash step, cells were 821 
analyzed on FACS AccuriTM C6 (BD Biosciences). Flow cytometry data analysis and mean 822 
fluorescence intensity (MFI) values were calculated by FlowJo analysis software (Tree Star) on 823 
live-gated cells (minimum of 20,000 cells). Percent internalization was calculated based on 824 
MFI values as follows: % internalization = (1 – MFI NDP-MSH stimulated/MFI unstimulated) 825 
x 100. Results are from four independent experiment. 826 
 827 
QUANTIFICATION AND STATISTICAL ANALYSIS  828 
Results were analyzed using GraphPad Prism 7 (Graph Pad Software), STATA v14.2 (StataCorp, 829 
College Station, Texas 77845 USA), R v3.2.2 (The R Foundation for Statistical Computing). For 830 
cAMP, β-arrestin and ERK1/2 assays, the difference between WT and mutant MC4Rs was 831 
tested using an unpaired single-sample t-test assigning a value of 100% for WT. The signaling 832 
bias for GoF variants of MC4R was estimated by calculating the ratio of geometric means for 833 
Emax β-arrestin to Emax cAMP and its 95% confidence interval using unpaired two-sample t-834 
test, with a null hypothesis of no bias (i.e. ratio=1). Studies in cellular models are from at least 835 
3 independent experiments. All p-values reported in this manuscript are from 2-sided 836 
statistical tests. A P<0.05 was considered statistically significant. In figures, statistical 837 
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SUPPLEMENTAL TABLES TITLES AND LEGENDS 842 
 843 
Table S1. Characteristics of European ancestry participants of UK Biobank and of the 844 
nonsynonymous genetic variants in MC4R included in this study. Related to Figure 1. 845 
 846 
Table S2. Functional characterization of MC4R variants identified in UK Biobank. Related to 847 
Figure 1. 848 
 849 
Table S3. Association of gain-of-function and loss-of-function variants in MC4R with blood 850 
pressure and resting heart rate. Related to Figure 1. 851 
 852 
Table S4. Associations with Body Mass Index in sensitivity and validation analyses. Related to 853 
Figure 1. 854 
 855 
Table S5. Meta-regression analyses investigating whether in vitro cAMP production or β-856 
arrestin recruitment explain variance in the associations of MC4R variants with BMI. Related 857 
to Figure 2. 858 
 859 
Table S6. Associations of cAMP-biased gain-of-function variants in MC4R with continuous 860 
traits and disease outcomes. Related to Figure 3. 861 
 862 
Table S7. Association of the gain-of-function variant V103I MC4R with continuous traits and 863 
disease outcomes. Related to Figure 4. 864 
 865 
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Table S8. Functional characterization of V103I MC4R. Related to Figure 4. 866 
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